Kalaris Therapeutics, Inc. · NASDAQ:KLRS

Kalaris Therapeutics — American Society of Retina Specialists Annual Meeting (December 2025)

11 slides from Kalaris Therapeutics's conference presentation, December 2025

  1. Slide 1: First-in-Human Evaluation of TH103, a Novel Dual-Targeting VEGF/HSPG Biologic

    First-in-Human Evaluation of TH103, a Novel Dual-Targeting VEGF/HSPG Biologic: Phase 1 Single Ascending Dose Study in Treatment-Naïve Neovascular AMD Joel Pearlman, MD, Principal Investigator Retinal Consultants Medical Group 1

  2. Slide 2: Financial Disclosures: Research Support

    Financial Disclosures: Research Support • 4D Molecular Therapeutics, Inc. • GSK plc • Amgen Inc. • Hexal AG / Sandoz Group AG • Annexon, Inc. • Kalaris Therapeutics, Inc. • Apellis Pharmaceuticals, Inc. • Kodiak Sciences Inc. • Aviceda Therapeutics, Inc. • Merck & Co., Inc. • Bayer AG • Oculis Holdi

  3. Slide 3: VEGFR1 domain 3 enables potential TH103 binding to retina

    VEGFR1 domain 3 enables potential TH103 binding to retina TH103 aflibercept Domain 3 from VEGFR1: In contrast, domain 3 from VEGFR2: Binds strongly to HSPG which are present Binds less strongly to HSPG, leading to in all retinal layers, thereby sequestering reduced tissue sequestration (preferred fo

  4. Slide 4: Phase 1a Single Ascending Dose (SAD) Study in Treatment-Naïve nAMD

    Phase 1a Single Ascending Dose TH103 5.0 mg (SAD) Study in TH103 Treatment-Naïve TH103 2.5 mg nAMD TH103 1.5 mg Multi-center U.S. study to 0.5 mg evaluate safety, tolerability, pharmacokinetics, and anti- Study Details VEGF activity following a single ● Primary timepoint for analysis at Month 1 inje

  5. Slide 5: Key baseline characteristics of patients in Phase 1a SAD trial of TH103

    Key baseline characteristics of patients in Phase 1a SAD trial of TH103 Tx.-Naïve (efficacy analysis population) Including Tx-Experienced Additional Tx- Dec. 2025 Data All Tx.-Naïve Tx.-Experienced2 All Patients2 Naïve Patients Release (n=13) Patients (n=17) (n=3) (n=20) (n=4)4 Age (mean) 78 76 78 8

  6. Slide 6: Mean 9.2 letter gain in BCVA after a single TH103 injection at Month 1

    Mean 9.2 letter gain in BCVA letter score after a single TH103 injection at Month 1 Mean BCVA Change Over Time 10 +9.2 letters 9 8 7 ETDRS Letters 6 5 4 53% ≥10 letter gain 3 2 1 0 D1 D2 D4 W1 W2 M1 Time ETDRS = Early Treatment Diabetic Retinopathy Study Note: n = 17 at all timepoints except Month 1

  7. Slide 7: Rapid, robust improvement in CST and retinal fluid volume at Week 1 and Month 1

    Rapid, robust improvement in CST and total retinal fluid (TRF) & intraretinal fluid (IRF) volume at Week 1 and Month 1 Mean CST Change Over Time1 Case Example (1.5 mg) 0 -20 -40 Mean 89% and 99% Mean 89% and 93% CST Change (𝛍𝛍m) resolution of TRF and -60 IRF by Week 12 resolution of TRF and…

  8. Slide 8: Single-dose durability signal suggests potential for stronger durability outcomes

    Single-dose durability signal suggests Phase 1a Single-Dose Time to Retreatment (n = 17, Tx-naïve) potential for stronger durability outcomes Time to first retreatment 41% ≥ 4M after standard four- dose loading regimen, Time to first retreatment 35% ≥ 5M currently being evaluated in ongoing Ph 1b/2

  9. Slide 9: Durability signal: intraocular retention and extended treatment intervals

    Durability signal: intraocular retention and extended treatment intervals ✓ Pharmacokinetics: 27–53× lower plasma Cmax/dose1 than Eylea, Eylea HD, and Vabysmo — consistent with greater intraocular retention ✓ Time to retreatment: • After one TH103 dose (n=17, treatment-naïve): 41% reached ≥4 months,

  10. Slide 10: Safety Summary from Phase 1a SAD Trial

    Safety Summary from Phase 1a SAD Trial ● No dose limiting toxicity (DLT) or treatment-emergent serious adverse events (SAEs) observed ● Transient, mild-moderate intraocular inflammation (IOI) presented at Day 4 in 2 patients dosed at 2.5mg with TH103 manufacturing batch #11 ● No cases of IOI in 6 pa

  11. Slide 11: New Phase 1a SAD data support TH103's potential as best-in-class first-line treatment

    New Phase 1a SAD data continue to support TH103’s potential as best-in-class, first-line treatment for retinal vascular diseases ✓ Efficacy: rapid, robust response on BCVA and OCT parameters observed across dose levels at one month - Mean 9.2-letter BCVA improvement at Month 1 after one TH103 inject

Kalaris Therapeutics — American Society of Retina Specialists Annual Meeting (December 2025) on 6ix